Publications / News

August 28, 2023
Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes
August 26, 2023
Circulating dipeptidyl peptidase 3 – New hope for a specific treatment to improve prognosis in cardiogenic shock?
August 24, 2023
DPP3 appreciated as promising biomarker for shock diagnosis and shock therapy
January 05, 2022
The emerging role of dipeptidyl peptidase 3 in pathophysiology
January 04, 2022
Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure?
January 01, 2022
Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis
December 08, 2021
High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort.
August 24, 2021
Circulating dipeptidyl peptidase 3 on intensive care unit admission is a predictor of organ dysfunction and mortality
June 01, 2021
Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome
June 01, 2021
Circulating biomarkers to assess cardiovascular function in critically ill
March 15, 2021
Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage
February 21, 2021
Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study.
December 30, 2020
Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.
November 20, 2020
In-hospital mortality and organ failure after open and endovascular thoraco-abdominal aortic surgery can be predicted by increased levels of circulating dipeptidyl peptidase 3.